Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 5Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 382Carboplatin 279Specimen Handling 266Nivolumab 256Magnetic Resonance Spectroscopy 247Cyclophosphamide 242Cisplatin 217Paclitaxel 208Radiotherapy 196Biopsy 171Gemcitabine 158Dexamethasone 149durvalumab 148atezolizumab 128Rituximab 123Doxorubicin 117Bevacizumab 115Ipilimumab 114Lenalidomide 113Radiation 111Pemetrexed 104Docetaxel 104Etoposide 102venetoclax 98fludarabine 97Radiosurgery 94Capecitabine 94Fluorouracil 93Oxaliplatin 91Prednisone 90

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Combined Modality Therapy × 1 year × Clear all
NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07142421 2025-08-26

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

First Affiliated Hospital of Zhejiang University

Phase 2 Active not recruiting
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07018427 2025-06-12

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Peking University Cancer Hospital & Institute

Active not recruiting
70 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡